IL145087A0 - A means for the prophylactic and therapeutic treatment of streptococcal infections - Google Patents

A means for the prophylactic and therapeutic treatment of streptococcal infections

Info

Publication number
IL145087A0
IL145087A0 IL14508799A IL14508799A IL145087A0 IL 145087 A0 IL145087 A0 IL 145087A0 IL 14508799 A IL14508799 A IL 14508799A IL 14508799 A IL14508799 A IL 14508799A IL 145087 A0 IL145087 A0 IL 145087A0
Authority
IL
Israel
Prior art keywords
prophylactic
subject
therapeutic treatment
streptococcal infections
survival rate
Prior art date
Application number
IL14508799A
Other languages
English (en)
Original Assignee
New Horizons Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Horizons Diagnostics Inc filed Critical New Horizons Diagnostics Inc
Priority claimed from PCT/US1999/004063 external-priority patent/WO2000050069A1/en
Publication of IL145087A0 publication Critical patent/IL145087A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14508799A 1999-01-11 1999-02-25 A means for the prophylactic and therapeutic treatment of streptococcal infections IL145087A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/227,852 US6350464B1 (en) 1999-01-11 1999-01-11 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
PCT/US1999/004063 WO2000050069A1 (en) 1999-02-25 1999-02-25 A means for the prophylactic and therapeutic treatment of streptococcal infections

Publications (1)

Publication Number Publication Date
IL145087A0 true IL145087A0 (en) 2002-06-30

Family

ID=22854735

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14508799A IL145087A0 (en) 1999-01-11 1999-02-25 A means for the prophylactic and therapeutic treatment of streptococcal infections
IL14408799A IL144087A0 (en) 1999-01-11 1999-12-23 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL14408799A IL144087A0 (en) 1999-01-11 1999-12-23 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same

Country Status (20)

Country Link
US (4) US6350464B1 (cs)
EP (1) EP1140028B1 (cs)
JP (1) JP2002534456A (cs)
KR (1) KR20010101472A (cs)
CN (1) CN1337878A (cs)
AT (1) ATE310506T1 (cs)
AU (1) AU779182B2 (cs)
BR (1) BR9916881A (cs)
CA (1) CA2359109C (cs)
CZ (1) CZ20012416A3 (cs)
DE (1) DE69928567T2 (cs)
HU (1) HUP0202670A3 (cs)
IL (2) IL145087A0 (cs)
IN (1) IN2001CH01053A (cs)
MX (1) MX236541B (cs)
NO (1) NO20013402L (cs)
RU (1) RU2001122708A (cs)
TR (1) TR200102012T2 (cs)
WO (1) WO2000041678A1 (cs)
ZA (1) ZA200106499B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4697099A (en) 1998-06-18 2000-01-05 Johns Hopkins University School Of Medicine, The Polymers for delivery of nucleic acids
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
WO2001010416A1 (en) * 1999-08-11 2001-02-15 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
AU2001270310A1 (en) * 2000-07-07 2002-01-21 Guilford Pharmaceuticals Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
US20020045668A1 (en) * 2000-07-17 2002-04-18 Wenbin Dang Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001296800A1 (en) * 2000-10-06 2002-04-15 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
AU2002215333A1 (en) * 2000-10-12 2002-04-22 Guilford Pharmaceuticals Inc. Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same
US20030133903A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of prostate cancers and methods of making and using the same
WO2003060799A2 (en) * 2002-01-09 2003-07-24 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US7871573B2 (en) * 2004-07-26 2011-01-18 University Of Louisville Research Foundation, Inc. Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging
US8563328B2 (en) * 2004-07-26 2013-10-22 University Of Louisville Research Foundation, Inc. Fiber-optic biosensor and biosensing methods
US7517914B2 (en) * 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
US7846361B2 (en) 2006-07-20 2010-12-07 Orbusneich Medical, Inc. Bioabsorbable polymeric composition for a medical device
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
CA2708514A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2010037021A2 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010132763A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
AU2012284147A1 (en) * 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
US10058688B2 (en) * 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA597473A (en) 1960-05-03 Starck Werner Process for the manufacture of phosphorus-containing polyesters and copolymers thereof
US2891915A (en) 1954-07-02 1959-06-23 Du Pont Organophosphorus polymers
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (cs) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CA2180260A1 (en) 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996022786A1 (en) 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
WO1997040085A2 (en) 1996-04-23 1997-10-30 Kinerton Limited Acidic polylactic polymers
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
AU744095B2 (en) 1997-03-27 2002-02-14 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
EP0973818B1 (en) 1997-04-03 2004-10-13 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
KR20010020432A (ko) 1997-04-30 2001-03-15 토마스 씨. 서 폴리(고리지방족 포스포에스테르) 화합물로 이루어진 생분해성 조성물, 약품 및 그의 이용방법
US6008318A (en) 1997-06-18 1999-12-28 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
EP1117441A2 (en) 1998-10-02 2001-07-25 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents

Also Published As

Publication number Publication date
IL144087A0 (en) 2002-05-23
US20010038849A1 (en) 2001-11-08
CZ20012416A3 (cs) 2001-11-14
AU2059100A (en) 2000-08-01
HUP0202670A2 (hu) 2002-11-28
ZA200106499B (en) 2002-11-07
US6350464B1 (en) 2002-02-26
WO2000041678A1 (en) 2000-07-20
EP1140028B1 (en) 2005-11-23
NO20013402L (no) 2001-09-11
US20040071774A1 (en) 2004-04-15
HUP0202670A3 (en) 2003-02-28
KR20010101472A (ko) 2001-11-14
MXPA01007018A (es) 2005-07-01
RU2001122708A (ru) 2004-02-20
US6479067B2 (en) 2002-11-12
TR200102012T2 (tr) 2002-01-21
DE69928567T2 (de) 2006-08-17
AU779182B2 (en) 2005-01-13
CA2359109C (en) 2011-02-22
US20030138493A1 (en) 2003-07-24
JP2002534456A (ja) 2002-10-15
BR9916881A (pt) 2002-05-07
MX236541B (es) 2006-05-04
NO20013402D0 (no) 2001-07-09
CN1337878A (zh) 2002-02-27
ATE310506T1 (de) 2005-12-15
CA2359109A1 (en) 2000-07-20
EP1140028A1 (en) 2001-10-10
IN2001CH01053A (en) 2005-03-04
US6641833B2 (en) 2003-11-04
DE69928567D1 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
IL145087A0 (en) A means for the prophylactic and therapeutic treatment of streptococcal infections
CA2292359A1 (en) Novel azalides and methods of making same
AP1553A (en) Tricyclic inhibitors of poly (ADP-Ribose) polymerases.
AP2001002222A0 (en) Ketolide antibiotics.
IL145492A0 (en) Methods and compositions for treating solid tumors
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
YU41500A (sh) Novi makrolidi
PL342614A1 (en) Anticarcinogenic drugs
MX9800945A (es) Uso de griseofulvina para inhibir el crecimiento de canceres.
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
MX2007005275A (es) Composicion antiviral.
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
CA2374902A1 (en) Aminoalkyl substituted benzopyran derivatives for treating impaired fundic relaxation
YU46302A (sh) Supstituisani piroli
AP9801235A0 (en) Erythromycin derivatives.
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
AP2002002494A0 (en) Hygromycin derivatives.
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı
YU43302A (sh) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.